IP Library › Granted Patent US 12,365,936
Granted Patent B2
US 12,365,936 · App. 18/319,244 · Granted Jul 22, 2025

Spatial sequencing of modified sequences

Inventor: Eli N. Glezer (Del Mar, CA)
Assignee: Singular Genomics Systems, Inc.
C12Q1/6841
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,936
App. No.
18/319,244
Granted
Jul 22, 2025
Kind
B2
Abstract

Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a sample comprising a cell.

Claims (73)

1. A method of sequencing a nucleic acid molecule, said method comprising:

(a) administering a genetically modifying agent to a subject, thereby generating an agent-modified target sequence; and

(b) detecting the agent-modified target sequence in a cell or tissue obtained from said subject, wherein the agent-modified target sequence forms part of an RNA molecule;

 wherein detecting the agent-modified target sequence comprises:

(i) contacting the cell or tissue with a polynucleotide probe and hybridizing a first end of the polynucleotide probe to a first sequence of the RNA molecule, and hybridizing a second end of the polynucleotide probe to a second sequence of the RNA molecule, wherein said RNA molecule comprises the agent-modified target sequence between the first sequence and the second sequence;

(ii) extending the polynucleotide probe along the agent-modified target sequence to generate a complement of the agent-modified target sequence, and ligating the complement of the agent-modified target sequence to the polynucleotide probe thereby forming a circular oligonucleotide; and

(iii) amplifying the circular oligonucleotide to generate an amplification product and sequencing a sequence of the amplification product.

2. The method of claim 1 , further comprising detecting a control sequence in a control cell or control tissue obtained from said subject, wherein said control cell or control tissue comprises a control RNA molecule.

3. The method of claim 2 , wherein detecting said control sequence comprises contacting the control cell or control tissue with a polynucleotide probe and hybridizing a first end of the polynucleotide probe to a first sequence of the control RNA molecule, and hybridizing a second end of the polynucleotide probe to a second sequence of the control RNA molecule, wherein said control RNA molecule comprises the control sequence between the first sequence and the second sequence; extending the polynucleotide probe along the control sequence to generate a complement of the control sequence, and ligating the complement of the control sequence to the polynucleotide probe thereby forming a control circular oligonucleotide; amplifying the control circular oligonucleotide to generate a control amplification product and sequencing a sequence of the control amplification product.

4. The method of claim 2 , wherein said agent-modified target sequence comprises one or more mutations relative to said control sequence.

5. The method of claim 1 , wherein sequencing comprises extending a sequencing primer by incorporating a labeled nucleotide, or labeled nucleotide analogue, and detecting the label for each incorporated nucleotide or nucleotide analogue, wherein the sequencing primer is hybridized to the amplification product.

6. The method of claim 5 , wherein the labeled nucleotide or labeled nucleotide analogue further comprises a reversible terminator moiety.

7. The method of claim 1 , further comprising detecting a plurality of target sequences from the cell or tissue.

8. The method of claim 7 , wherein the plurality of target sequences are different sequences of the same nucleic acid molecule.

9. The method of claim 1 , wherein the cell is an endothelial cell, muscle cell, myocardial cell, smooth muscle cell, skeletal muscle cell, mesenchymal cell, epithelial cell, or hematopoietic cell.

10. The method of claim 1 , wherein the cell is a stem cell, an immune cell, a cancer cell, or a viral-host cell.

11. The method of claim 1 , wherein the cell is a cancer cell.

12. The method of claim 1 , wherein the cell is an immune cell.

13. The method of claim 1 , wherein the genetically modifying agent is a small molecule, protein, pathogen, toxin, oligonucleotide, or antigen.

14. The method of claim 1 , wherein the genetically modifying agent is a virus and the agent-modified target sequence is a nucleic acid sequence that develops within a T cell or B cell upon cellular exposure and contact with the virus.

15. The method of claim 14 , wherein the genetically modifying agent is an RNA virus.

16. The method of claim 1 , wherein the genetically modifying agent is a pharmaceutical agent.

17. The method of claim 1 , further comprising detecting a protein of said cell or tissue.

18. The method of claim 17 , comprising

contacting the cell or tissue with an antibody comprising a nucleic acid molecule and binding the antibody to the protein; binding a polynucleotide to the nucleic acid molecule; and detecting the polynucleotide, thereby detecting the protein.

19. The method of claim 1 , comprising immobilizing the cell or tissue to a solid support.

20. The method of claim 1 , wherein the agent-modified target sequence is 1 to 25 nucleotides.

21. The method of claim 1 , wherein the agent-modified target sequence is 5 to 150 nucleotides.

22. The method of claim 1 , wherein the agent-modified target sequence is about 20 to about 80 nucleotides.

23. The method of claim 1 , further comprising imaging said cell or tissue.

24. The method of claim 1 , wherein said polynucleotide probe comprises one or more LNA nucleotides in the first end or in the second end.

25. The method of claim 1 , wherein said tissue comprises liver tissue, kidney tissue, bone tissue, lung tissue, thymus tissue, adrenal tissue, skin tissue, bladder tissue, colon tissue, spleen tissue, or brain tissue.

26. The method of claim 1 , wherein said tissue comprises breast tissue, lung tissue, colon tissue, lymph tissue, kidney tissue, bone tissue, tonsil tissue, or brain tissue.

27. The method of claim 1 , wherein sequencing comprises repeated cycles of labeled oligonucleotide hybridization and detection.

28. The method of claim 1 , wherein the RNA molecule encodes for a chimeric antigen receptor.

29. The method of claim 1 , wherein the RNA molecule is transcribed from a T cell receptor alpha variable gene sequence (TRAV gene), T cell receptor alpha joining gene sequence (TRAJ gene), T cell receptor alpha constant gene sequence (TRAC gene), T cell receptor beta variable gene sequence (TRBV gene), T cell receptor beta diversity gene sequence (TRBD gene), T cell receptor beta joining gene sequence (TRBJ gene), T cell receptor beta constant gene sequence (TRBC gene), T cell receptor gamma variable gene sequence (TRGV gene), T cell receptor gamma joining gene sequence (TRGJ gene), T cell receptor gamma constant gene sequence (TRGC gene), T cell receptor delta variable gene sequence (TRDV gene), T cell receptor delta diversity gene sequence (TRDD gene), T cell receptor delta joining gene sequence (TRDJ gene), or T cell receptor delta constant gene sequence (TRDC gene).

30. The method of claim 1 , wherein the RNA molecule is transcribed from a T cell receptor alpha (TCRA) gene sequence or a T cell receptor beta (TCRB) gene sequence.

31. The method of claim 1 , wherein amplifying the circular oligonucleotide generates an amplification product comprising one or more copies of the agent-modified target sequence, and sequencing a sequence of the amplification product comprises sequencing the one or more copies of the agent-modified target sequence.

32. A method of incorporating a modified nucleotide into a nucleic acid molecule in a cell or tissue, said method comprising:

administering a genetically modifying agent to a subject, thereby generating an agent-modified target sequence;

obtaining a cell or tissue obtained from said subject;

contacting the cell or tissue with a polynucleotide probe and hybridizing a first end of the polynucleotide probe to a first sequence of an RNA molecule, and hybridizing a second end of the polynucleotide probe to a second sequence of the RNA molecule, wherein said nucleic acid molecule comprises the agent-modified target sequence between the first sequence and the second sequence;

extending the polynucleotide probe along the agent-modified target sequence to generate a complement of the agent-modified target sequence, and ligating the complement of the agent-modified target sequence to the polynucleotide probe thereby forming a circular oligonucleotide; and

amplifying the circular oligonucleotide to form an extension product;

hybridizing a primer to the extension product and incorporating a modified nucleotide into the primer, wherein the modified nucleotide comprises a reversible terminator.

33. The method of claim 32 , further comprising removing the reversible terminator and incorporating a second modified nucleotide into the primer.

34. The method of claim 32 , wherein the modified nucleotide comprises a detectable label.

35. The method of claim 34 , further comprising detecting the modified nucleotide, thereby identifying a complementary nucleotide of the extension product.

36. A method of sequencing a nucleic acid molecule, said method comprising:

(a) delivering a genetically modifying agent to a cell, thereby generating an agent-modified target sequence; and

(b) detecting the agent-modified target sequence in the cell, wherein the cell is immobilized to a solid support and the agent-modified target sequence forms part of an RNA molecule;

wherein detecting the agent-modified target sequence comprises:

(i) contacting the cell with a polynucleotide probe and hybridizing a first end of the polynucleotide probe to a first sequence of the RNA molecule, and hybridizing a second end of the polynucleotide probe to a second sequence of the RNA molecule, wherein said RNA molecule comprises the agent-modified target sequence between the first sequence and the second sequence;

(ii) extending the polynucleotide probe along the agent-modified target sequence to generate a complement of the agent-modified target sequence, and ligating the complement of the agent-modified target sequence to the polynucleotide probe thereby forming a circular oligonucleotide; and

(iii) amplifying the circular oligonucleotide to generate an amplification product and sequencing a sequence of the amplification product in the cell.

37. The method of claim 36 , wherein during (a) the cell is within an organism.

38. The method of claim 36 , wherein delivering a genetically modifying agent to a cell and detecting the agent-modified target sequence in the cell occur in the same reaction vessel.

39. The method of claim 36 , wherein amplifying the circular oligonucleotide generates an amplification product comprising one or more copies of the agent-modified target sequence, and sequencing a sequence of the amplification product comprises sequencing the one or more copies of the agent-modified target sequence.

40. The method of claim 36 , wherein sequencing comprises extending a sequencing primer by incorporating a labeled nucleotide, or labeled nucleotide analogue, and detecting the label for each incorporated nucleotide or nucleotide analogue, wherein the sequencing primer is hybridized to the amplification product.

41. The method of claim 36 , wherein sequencing comprises repeated cycles of labeled oligonucleotide hybridization and detection.

42. The method of claim 36 , wherein the cell is an endothelial cell, muscle cell, myocardial cell, smooth muscle cell, skeletal muscle cell, mesenchymal cell, epithelial cell, or hematopoietic cell.

43. The method of claim 36 , wherein the cell is an immune cell.

44. The method of claim 36 , wherein the genetically modifying agent is a small molecule, protein, pathogen, toxin, oligonucleotide, or antigen.

45. The method of claim 36 , wherein the genetically modifying agent is a virus and the agent-modified target sequence is a nucleic acid sequence that develops within a T cell or B cell upon cellular exposure and contact with the virus.

46. The method of claim 45 , wherein the genetically modifying agent is an RNA virus.

47. The method of claim 36 , wherein the genetically modifying agent is a pharmaceutical agent.

48. The method of claim 36 , further comprising detecting a protein of said cell.

49. The method of claim 48 , comprising

contacting the cell with an antibody comprising a nucleic acid molecule and binding the antibody to the protein; binding a polynucleotide to the nucleic acid molecule; and detecting the polynucleotide, thereby detecting the protein.

50. The method of claim 36 , wherein the agent-modified target sequence is 1 to 25 nucleotides.

51. The method of claim 36 , wherein the agent-modified target sequence is 5 to 150 nucleotides.

52. The method of claim 36 , wherein the agent-modified target sequence is about 20 to about 80 nucleotides.

53. The method of claim 36 , further comprising imaging said cell.

Assignments (2)
SECURITY INTEREST Recorded Mar 7, 2025
From: SINGULAR GENOMICS SYSTEMS, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 070440/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: GLEZER, ELI N.
To: SINGULAR GENOMICS SYSTEMS, INC
Reel/Frame 064472/0593 →
Continuity (7)
Continuation 18045913 · Oct 12, 2022
Continuation 17815542 · Jul 27, 2022
Continuation 17396579 · Aug 6, 2021
Provisional Application 63209903 · Jun 11, 2021
Provisional Application 63140703 · Jan 22, 2021
Provisional Application 63062047 · Aug 6, 2020
Related Publication 20230357828A1 · Nov 9, 2023
References Cited (178)
US 6218122B1 · Friend et al. · 2001 [cited by applicant]
US 6271022B1 · Bochner · 2001 [cited by applicant]
US 6365367B1 · Friedman et al. · 2002 [cited by applicant]
US 7390463B2 · He et al. · 2008 [cited by applicant]
US 8551710B2 · Bernitz et al. · 2013 [cited by applicant]
US 9371598B2 · Chee · 2016 [cited by applicant]
US 9556473B2 · Bernitz et al. · 2017 [cited by applicant]
US 9593365B2 · Frisen et al. · 2017 [cited by applicant]
US 10059990B2 · Boyden et al. · 2018 [cited by applicant]
US 10138509B2 · Church et al. · 2018 [cited by applicant]
US 10266888B2 · Daugharthy et al. · 2019 [cited by applicant]
US 10323272B1 · Rabbani et al. · 2019 [cited by applicant]
US 10495554B2 · Deisseroth et al. · 2019 [cited by applicant]
US 10774374B2 · Frisen et al. · 2020 [cited by applicant]
US 11434525B2 · Glezer · 2022 [cited by examiner]
US 11492662B2 · Glezer et al. · 2022 [cited by applicant]
US 11643679B2 · Glezer et al. · 2023 [cited by applicant]
US 11680288B2 · Glezer · 2023 [cited by examiner]
US 11753678B2 · Glezer · 2023 [cited by applicant]
US 11891656B2 · Glezer et al. · 2024 [cited by applicant]
US 12006534B2 · Glezer · 2024 [cited by applicant]
US 20010053519A1 · Fodor et al. · 2001 [cited by applicant]
US 20010054691A1 · Park et al. · 2001 [cited by applicant]
US 20020064779A1 · Landegren et al. · 2002 [cited by applicant]
US 20030049862A1 · He et al. · 2003 [cited by applicant]
US 20030077580A1 · Catanzariti et al. · 2003 [cited by applicant]
US 20040137484A1 · Zhang et al. · 2004 [cited by applicant]
US 20040248318A1 · Weinberger et al. · 2004 [cited by applicant]
US 20050130173A1 · Leamon et al. · 2005 [cited by applicant]
US 20050142556A1 · Hoon et al. · 2005 [cited by applicant]
US 20050287526A1 · Landegren et al. · 2005 [cited by applicant]
US 20050287578A1 · Davis · 2005 [cited by applicant]
US 20060050376A1 · Houston et al. · 2006 [cited by applicant]
US 20060292559A1 · Reddy et al. · 2006 [cited by applicant]
US 20090048119A1 · Krjutskov et al. · 2009 [cited by applicant]
US 20090298718A1 · Denman et al. · 2009 [cited by applicant]
US 20110223585A1 · Gullberg et al. · 2011 [cited by applicant]
US 20120301886A1 · Farrell et al. · 2012 [cited by applicant]
US 20130296535A1 · Church et al. · 2013 [cited by applicant]
US 20140120534A1 · Bernitz et al. · 2014 [cited by applicant]
US 20140170654A1 · Landegren et al. · 2014 [cited by applicant]
US 20150225778A1 · Hindson et al. · 2015 [cited by applicant]
US 20160108392A1 · Stelling · 2016 [cited by applicant]
US 20160116384A1 · Chen et al. · 2016 [cited by applicant]
US 20160145696A1 · Brandon et al. · 2016 [cited by applicant]
US 20160257993A1 · Fu et al. · 2016 [cited by applicant]
US 20170067925A1 · Spence et al. · 2017 [cited by applicant]
US 20180037943A1 · Rothwell et al. · 2018 [cited by applicant]
US 20180187242A1 · Makrigiorgos et al. · 2018 [cited by applicant]
US 20190017106A1 · Frisen et al. · 2019 [cited by applicant]
US 20190055594A1 · Samusik et al. · 2019 [cited by applicant]
US 20190064109A1 · Brown et al. · 2019 [cited by applicant]
US 20190071668A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190113423A1 · Goodman et al. · 2019 [cited by applicant]
US 20190119735A1 · Deisseroth et al. · 2019 [cited by applicant]
US 20190155835A1 · Daugharthy et al. · 2019 [cited by applicant]
US 20190161796A1 · Hauling et al. · 2019 [cited by applicant]
US 20190241945A1 · Malyshev et al. · 2019 [cited by applicant]
US 20190241950A1 · Daugharthy et al. · 2019 [cited by applicant]
US 20190264279A1 · Kain et al. · 2019 [cited by applicant]
US 20190391140A1 · Aghvanyan et al. · 2019 [cited by applicant]
US 20200032334A1 · Hubbell · 2020 [cited by applicant]
US 20200071751A1 · Daugharthy et al. · 2020 [cited by applicant]
US 20200124601A1 · Fan et al. · 2020 [cited by applicant]
US 20200140944A1 · Belgrader et al. · 2020 [cited by applicant]
US 20200224244A1 · Nilsson et al. · 2020 [cited by applicant]
US 20200224544A1 · Barker et al. · 2020 [cited by applicant]
US 20200271556A1 · Sarkar et al. · 2020 [cited by applicant]
US 20200277663A1 · Ramachandran Iyer et al. · 2020 [cited by applicant]
US 20200277664A1 · Frenz · 2020 [cited by applicant]
US 20210017596A1 · Tong et al. · 2021 [cited by applicant]
US 20210164029A1 · Sekedat et al. · 2021 [cited by applicant]
US 20210189481A1 · Glezer et al. · 2021 [cited by applicant]
US 20210238662A1 · Bava et al. · 2021 [cited by applicant]
US 20210262018A1 · Bava et al. · 2021 [cited by applicant]
US 20210292834A1 · Daugharthy et al. · 2021 [cited by applicant]
US 20210388424A1 · Bava · 2021 [cited by applicant]
US 20220229044A1 · Feldman et al. · 2022 [cited by applicant]
US 20220333174A1 · Glezer et al. · 2022 [cited by applicant]
US 20220403457A1 · Glezer et al. · 2022 [cited by applicant]
US 20230027467A1 · Fredriksson · 2023 [cited by applicant]
US 20230100215A1 · Glezer et al. · 2023 [cited by applicant]
US 20230366013A1 · Glezer · 2023 [cited by examiner]
WO WO2008042067A2 · 2008 [cited by examiner]
WO WO2017143317A1 · 2017 [cited by applicant]
WO WO2018091676A1 · 2018 [cited by applicant]
WO WO2019068880A1 · 2019 [cited by applicant]
WO WO2019084062A1 · 2019 [cited by examiner]
WO WO2019195346A1 · 2019 [cited by applicant]
WO WO2019199579A1 · 2019 [cited by applicant]
WO WO2019222284A1 · 2019 [cited by examiner]
WO WO2020076976A1 · 2020 [cited by applicant]
WO WO2020076979A1 · 2020 [cited by applicant]
WO WO2020096687A1 · 2020 [cited by applicant]
WO WO2020099640A1 · 2020 [cited by applicant]
WO WO2020102766A2 · 2020 [cited by applicant]
WO WO2022032195A2 · 2022 [cited by applicant]
WO WO2022235764A1 · 2022 [cited by applicant]
Lundin, Spatiotemporal mapping of RNA editing in the developing mouse brain using in situ sequencing reveals regional and cell-type-specific regulation, BMC Biology, 18(6): 2020. (Year: 2020). [cited by examiner]
Tang, Suppression of rolling circle amplification by nucleotide analogs in circular template for three DNA polymerases, Biosci Biotech Biochem, 80(8): 1555-1561, 2016. (Year: 2016). [cited by examiner]
Ke, In situ seqeuncing for RNA analysis in preserved tissue and cells, Nature Methods, 10(9): 857-862, 2013. (Year: 2013). [cited by examiner]
Agrawal, S. et al. (Nov. 15, 2016). “Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy,” [cited by applicant]
Ahern, H. (1995) “Biochemical, reagent kits offer scientists good return on investment,” [cited by applicant]
Alon, S. et al. (Jan. 29, 2021) “Expansion Sequencing: Spatially Precise In Situ Transcriptomics in Intact Biological Systems,” [cited by applicant]
Arce, S. et al. (Jul. 14, 2013). “Fast and accurate automated cell boundary determination for fluorescence microscopy,” [cited by applicant]
Bullinger, L. et al. (Apr. 15, 2004). “Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia,” [cited by applicant]
Carow, B. et al. (Apr. 23, 2019). “Spatial and temporal localization of immune transcripts defines hallmarks and diversity in the tuberculosis granuloma,” [cited by applicant]
Carpenter, A. E. et al (Oct. 31, 2016). “CellProfiler: image analysis software for identifying and quantifying cell phenotypes,” [cited by applicant]
Chen, F. et al. (Jan. 30, 2015, e-published Jan. 15, 2015). “Optical imaging. Expansion microscopy,” [cited by applicant]
Chen, K. H. et al. (Apr. 24, 2015, e-published Apr. 9, 2015). “RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells,” [cited by applicant]
Christian, A. T. et al. (Dec. 4, 2001, e-published Nov. 27, 2001). “Detection of DNA point mutations and mRNA expression levels by rolling circle amplification in individual cells,” [cited by applicant]
Edelman, M. J. et al. (May 1997, e-published Feb. 28, 2002). “The utility of follow-up testing after curative cancer therapy: a critical review and economic analysis,” [cited by applicant]
El-Sagheer, A. H. et al. (Aug. 21, 2012, e-published Mar. 22, 2012).“Click nucleic acid ligation: applications in biology and nanotechnology,” [cited by applicant]
Gelali, E. et al. (Apr. 9, 2019). “iFISH is a publically available resource enabling versatile DNA FISH to study genome architecture,” [cited by applicant]
Gore, A. et al. (Mar. 3, 2011, e-published Mar. 2, 2011). “Somatic coding mutations in human induced pluripotent stem cells,” [cited by applicant]
Guo, J. et al. (Jul. 8, 2008). “Four-color DNA sequencing with 3′-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides,” [cited by applicant]
Gyllborg, D. et al. (Nov. 4, 2020, e-published Sep. 29, 2020). “Hybridization-based in situ sequencing (HybISS) for spatially resolved transcriptomics in human and mouse brain tissue,” [cited by applicant]
Hagai, T. et al. (Nov. 2018, e-published Oct. 24, 2018). “Gene expression variability across cells and species shapes innate immunity,” [cited by applicant]
Heintzmann, R. et al. (Dec. 13, 2017, e-published Nov. 10, 2017). “Super-Resolution Structured Illumination Microscopy,” [cited by applicant]
International Search Report and Written Opinion mailed on Jan. 31, 2022 for PCT Application No. PCT/US2021/045105, filed Aug. 6, 2021, 18 pages. [cited by applicant]
Jeong, S. et al. (Apr. 2020, e-published Jan. 30, 2020). “Current immunoassay methods and their applications to clinically used biomarkers of breast cancer,” [cited by applicant]
Kappler, K. et al. (Aug. 2020, e-published Aug. 5, 2020). “Emergence and significance of carbohydrate-specific antibodies,” [cited by applicant]
Klein A. M. et al. (Aug. 7, 2017, e-published Jul. 19, 2017). “InDrops and Drop-seq technologies for single-cell sequencing,” [cited by applicant]
Krzywkowski, T. et al. (Dec. 2019, e-published Oct. 11, 2018). “Chimeric padlock and iLock probes for increased efficiency of targeted RNA detection,” [cited by applicant]
Lareau, C. A. et al. (Feb. 13, 2020). “Inference and effects of barcode multiplets in droplet-based single-cell assays,” [cited by applicant]
Larsson, C. et al., (May 2010, e-published Apr. 11, 2010). “In situ detection and genotyping of individual mRNA molecules,” [cited by applicant]
Li, J. B. et al. (May 29, 2009). “Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing,” [cited by applicant]
Li, J. B. et al. (Sep. 2009, e-published Jun. 12, 2009). Multiplex padlock targeted sequencing reveals human hypermutable CpG variations, [cited by applicant]
Manuguerra, I. et al. (May 4, 2018, e-published Apr. 17, 2018). “Gene assembly via one-pot chemical ligation of DNA promoted by DNA nanostructures,” [cited by applicant]
Mignardi, M. et al. (Apr. 28, 2014). “Fourth-generation sequencing in the cell and the clinic,” [cited by applicant]
Nilsson, M. et al. (Sep. 30, 1994). “Padlock probes: circularizing oligonucleotides for localized DNA detection,” [cited by applicant]
Nitta, H. et al. (Aug. 2013, e-published Nov. 15, 2015). “New methods for ALK status diagnosis in non-small-Cell lung Cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC—In situ hybrid… [cited by applicant]
Odeh, F. et al. (Dec. 18, 2019). “Aptamers Chemistry: Chemical Modifications and Conjugation Strategies,” [cited by applicant]
Patel, A. P. et al. (Jun. 20, 2014, e-published Jun. 12, 2014). “Single-cell RNAseq highlights intratumoral heterogeneity in primary glioblastoma,” [cited by applicant]
Pearson, A. et al. (Aug. 1, 2016, e-published May 13, 2016). “High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial,” [cited by applicant]
Peters, J. M. et al. (Jan. 1, 2011). “Multiparameter flow cytometry in the diagnosis and management of acute leukemia,” [cited by applicant]
Porreca, G. J. et al. (Nov. 2007, e-published Oct. 14, 2007). “Multiplex amplification of large sets of human exons,” [cited by applicant]
Sansone, A. (Jun. 2019, e-published May 30, 2019). “Spatial transcriptomics levels up,” [cited by applicant]
Sapoznik, E. et al. (Nov. 12, 2020). “A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics,” [cited by applicant]
Schlachter, S. et al. (Dec. 7, 2009, e-published Nov. 30, 2009). “A method to unmix multiple fluorophores in microscopy images with minimal a priori information,” [cited by applicant]
Shirakawa, H. et al. (Mar. 2004). “Blind spectral decomposition of single-cell fluorescence by parallel factor analysis,” [cited by applicant]
Suzuki, A. et al. (Dec. 20, 2019). “Characterization of cancer omics and drug perturbations in panels of lung cancer cells,” [cited by applicant]
The Stratagene Catalog (1988), p. 39. [cited by applicant]
Van Der Velden, V. H. J. et al. (Jun. 2003, e-published May 23, 2003). “Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects,” [cited by applicant]
Vickovic, S. et al. (Oct. 2019, e-published Sep. 9, 2019). “High-definition spatial transcriptomics for in situ tissue profiling,” [cited by applicant]
Wang, G. et al. (Mar. 19, 2018). “Multiplexed imaging of high-density libraries of RNAs with MERFISH and expansion microscopy,” [cited by applicant]
Wilson, C. S. et al. (Jul. 15, 2006, e-published Apr. 4, 2006). “Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction,” [cited by applicant]
York, A. G. et al. (Nov. 2013, e-published Oct. 6, 2013). “Instant superresolution imaging in live cells and embryos via analog image processing,” [cited by applicant]
Zheng, G. X. et al. (Jan. 16, 2017). “Massively parallel digital transcriptional profiling of single cells,” [cited by applicant]
Catuogno, S. et al. (Apr. 8, 2011). “Recent advance in biosensors for microRNAs detection in cancer,” [cited by applicant]
Chen, X. et al. (Feb. 28, 2018, e-published Nov. 28, 2017). “Efficient in situ barcode sequencing using padlock probe-based BaristaSeq,” [cited by applicant]
Daigeler, A. et al. (Jul. 6, 2006). “Clinicopathological findings in a case series of extrathoracic solitary fibrous tumors of soft tissues,” [cited by applicant]
Denkert, C. et al. (Nov. 1, 2015, e-published Aug. 14, 2015). “Strategies for developing Ki67 as a useful biomarker in breast cancer,” [cited by applicant]
Fijnvandraat, A. C. et al. (Sep. 1, 2002, e-published Sep. 10, 2002). “Nonradioactive in situ detection of mRNA in ES cell-derived cardiomyocytes and in the developing heart,” [cited by applicant]
Fredriksson, S. et al. (Apr. 2007, e-published Mar. 18, 2007). “Multiplexed protein detection by proximity ligation for cancer biomarker validation,” [cited by applicant]
Fredriksson, S. et al. (May 1, 2002). “Protein detection using proximity-dependent DNA ligation assays,” [cited by applicant]
Gao, H. et al. (Dec. 2019, e-published Oct. 17, 2019) “Rolling circle amplification for single cell analysis and in situ sequencing,” [cited by applicant]
Ouladan, S. et al. (Jun. 2015, e-published Apr. 20, 2015). “Differential diagnosis of solitary fibrous tumors: A study of 454 soft tissue tumors indicating the diagnostic value of nuclear STAT6 relocation and ALDH1 expr… [cited by applicant]
Park, M. S. et al. (May 11, 2013). “The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis,” [cited by applicant]
Schallmeiner, E. et al. (Feb. 1, 2007, e-published Dec. 17, 2006). “Sensitive protein detection via triple-binder proximity ligation assays,” [cited by applicant]
Borkamo, E. D. et al. (Dec. 1, 2009, e-published Nov. 19, 2009). “cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy,” [cited by applicant]
Chen, X. et al. (Oct. 17, 2019). “High-throughput mapping of long-range neuronal projection using in situ sequencing,” [cited by applicant]
International Search Report and Written Opinion mailed on May 26, 2023 for PCT Application No. PCT/US2022/078941, filed Oct. 28, 2022, 16 pages. [cited by applicant]
Larimore, K. et al. (Sep. 15, 2012). “Shaping of human germline IgH repertoires revealed by deep sequencing,” [cited by applicant]
Extended European Search Report mailed Mar. 18, 2024, for EP Application No. 21852670.5, 13 pages. [cited by applicant]
Kohman, R. E. et al. (Apr. 28, 2020). “Fluorescent in situ sequencing of DNA barcoded antibodies,” [cited by applicant]
Strell, C et al. (Apr. 2019, e-published Mar. 14, 2019). “Placing RNA in context and space—methods for spatially resolved transcriptomics,” [cited by applicant]
Wang X. et al. (Jul. 27, 2018, e-published Jun. 21, 2018). “Three-dimensional intact-tissue sequencing of single-cell transcriptional states,” [cited by applicant]
Ambardar, S. et al. (Dec. 2016, e-published Jul. 9, 2016). “High throughput sequencing: an overview of sequencing chemistry,” [cited by applicant]
Conze, T. et al. (Jul. 2009, e-published Feb. 19, 2009). “Analysis of genes, transcripts, and proteins via DNA ligation,” [cited by applicant]
Frances-Soriano, L. et al. (Jan. 26, 2021, e-published Dec. 28, 2020). “In Situ rolling circle amplification Forster resonance energy transfer (RCA-FRET) for washing-free real-time single-protein imaging,” [cited by applicant]
Roussis, I. M. et al. (Mar. 3, 2017). “RNA whole-mount in situ hybridization proximity ligation assay (rISH-PLA), an assay for detecting RNA-protein complexes in intact cells,” [cited by applicant]
Söderberg, O. et al. (Dec. 2006, e-published Oct. 29, 2006). “Direct observation of individual endogenous protein complexes in situ by proximity ligation,” [cited by applicant]
You, Y. et al. (Apr. 1, 2006, e-published Jan. 1, 2006). “Design of LNA probes that improve mismatch discrimination,” [cited by applicant]
Zhang, D. et al. (Jan. 2006, e-published Aug. 24, 2005). “Amplification of circularizable probes for the detection of target nucleic acids and proteins,” [cited by applicant]
Konry, T. et al. (Feb. 7, 2011, e-published Dec. 27, 2010). “Ultrasensitive detection of low-abundance surface-marker protein using isothermal rolling circle amplification in a microfluidic nanoliter platform,” [cited by applicant]
Payne, A. C. (Jun. 2017, e-published Jul. 31, 2017). “Towards sequencing by synthesis in situ. Doctoral Dissertation.” [cited by applicant]
Wahlestedt, C. et al. (May 9, 2000). “Potent and nontoxic antisense oligonucleotides containing locked nucleic acids,” [cited by applicant]
Cited By (1)
US 12,529,093